Clinical Trials Logo

Clinical Trial Summary

The aim of this exploratory, hypothesis-generating study is to investigate the composition of the nasal microbiome in order to compare 1: COVID-positive and negative individuals, 2. Patients with smell loss and controls without smell loss; and 3. patients using intranasal glucocorticoids and non-users.


Clinical Trial Description

Hypotheses: The nasal microbiome in COVID-positive patients does not differ from healthy COVID-negative patients. The nasal microbiome in patients suffering from post COVID-19 olfactory dysfunction does not differ from healthy controls with normal olfaction. The nasal microbiome in non-COVID-patients with anosmia does not differ from non-COVID controls with normal sense of smell. Intra-nasal glucocorticoids do not affect the nasal microbiome. Methods: For all patients we will obtain a relevant medical history; an ear-, nose-, and throat examination; Sino-Nasal Outcome Test-22, score; Sniffin' Sticks TDI score; and taste screening results. The microbiome will be evaluated using swabs from the nasal cavity and analysed using next-generation sequencing targeting 16S and 18S ribosomal RNA at the Department of Bacteria, Parasite & Fungi at Staten Serum Institute, Copenhagen, Denmark. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05061329
Study type Observational [Patient Registry]
Source University of Aarhus
Contact Laura Marie Aalkjær Danielsen
Phone +4542714748
Email [email protected]
Status Recruiting
Phase
Start date December 21, 2020
Completion date September 1, 2023